baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

AbbVie Inc/ US00287Y1091 /

2024-07-26 9:59:58 PM	Chg. +2.91	Volume	Bid-	Ask-	Market Capitalization	Dividend Y.	P/E Ratio
185.14USD	+1.60%	225,492 Turnover: 41.82 mill.	-Bid Size: -	-Ask Size: -	326.97 bill.USD	3.24%	67.82

GlobeNewswire 07-01 Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

GlobeNewswire 07-01 OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in A...

GlobeNewswire 06-28 NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market

GlobeNewswire 06-28 Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Re...

GlobeNewswire 06-28 Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease

GlobeNewswire 06-27 Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Ach...

GlobeNewswire 06-26 COUR Pharmaceuticals Appoints Tim Walbert to its Board of Directors

GlobeNewswire 06-25 CEREVEL (NASDAQ:CERE) STOCK ALERT: Cerevel’s $45 Per Share Deal is Being Investigated by BFA Law, Sh...

GlobeNewswire 06-24 OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell...

GlobeNewswire 06-22 CEREVEL (NASDAQ:CERE) INVESTOR ALERT: Cerevel’s $45 Per Share Offer is Being Investigated by BFA Law...

GlobeNewswire 06-21 Antibody-drug Conjugates Shift the Cancer Treatment Landscape: Novotech Whitepaper Examines Latest C...

GlobeNewswire 06-20 CEREVEL INVESTOR REMINDER: Think $45 Per Share is Too Low for Cerevel (Nasdaq:CERE)? Contact BFA Law...

GlobeNewswire 06-20 OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of I...

GlobeNewswire 06-19 OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the B...

GlobeNewswire 06-19 Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

GlobeNewswire 06-18 CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Confere...

GlobeNewswire 06-18 CEREVEL STOCK UPDATE: Is $45 Per Share Enough for Cerevel (Nasdaq:CERE)? Contact BFA Law about Ongoi...

GlobeNewswire 06-17 CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

GlobeNewswire 06-17 Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, B...

GlobeNewswire 06-15 CEREVEL STOCK NOTICE: Think $45 Per Share is Too Low for Cerevel (Nasdaq: CERE)? Contact BFA Law abo...

Newsfile Corp 06-13 BioMed X Launches New US Institute in New Haven, CT

GlobeNewswire 06-13 Anima Biotech to Present at the Society for Medicines Research’s Modulating RNA with Oligonucleotide...

GlobeNewswire 06-13 LifeSci Advisors Announces Appointment of Chris Howerton Ph.D.

GlobeNewswire 06-13 CEREVEL SHAREHOLDER REMINDER: Is $45 Per Share Enough for Cerevel (Nasdaq: CERE)? BFA Law is Investi...

GlobeNewswire 06-13 What Employees at the Fortune Best Workplaces in New York, Chicago, Texas, and the Bay Area Value Mo...

AbbVie Inc/ US00287Y1091 /

If you wish to receive reply to your feedback, please provide your email address.